Compare Amcor PLC (AMCR) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amcor PLC vs CVS Health Corp — how do they compare? Amcor PLC trades at $43 (market cap $19.96B), while CVS Health Corp trades at $104.15 (market cap $132.89B). The key difference: CVS Health Corp is far larger — about 6.7× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| AMCR | CVS | |
|---|---|---|
Market Cap | $19.96B | $132.89B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $104.81 |
52-Week Low | $36.69 | $58.75 |
Enterprise Value | $35.08B | $199.43B |
Dividend Yield | 6.02% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
CVS Health trades at $104.15, up 1.3% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $2.57 exceeding expectations of $2.18. Revenue growth remains robust at $402.07B for 2025, though net margins have compressed to 0.72%. Recent dividend declarations and positive media coverage highlight the company's stable cash flow generation and market positioning.
CVS presents a compelling investment case with 84.6% analyst buy ratings and a $107.29 consensus target offering 3% upside. However, investors face risks from declining profitability margins, elevated debt levels at 25.48% debt-to-asset ratio, and competitive pressures in the healthcare sector. The stock's current valuation at 45.68 P/E requires careful monitoring of margin improvement initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
